GTHX G1 Therapeutics Inc.

+0.34  (+2%)
Previous Close 19.99
Open 20.16
Price To Book 1.99
Market Cap 755971701
Shares 37,185,032
Volume 140,736
Short Ratio
Av. Daily Volume 404,697

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 preliminary data noted ORR 37-43% across two arms. No CRs. PFS 8.8mths (HR 0.52, p=0.0669) and 7.3mths (HR 0.49; p=0.0546) across two arms. Combined PFS 7.9mths (HR 0.50, p=0.0189).
Triple-negative breast cancer
Phase 1b/2 preliminary data due 4Q 2019.
Tagrisso and G1T38
EGFR mutation-positive non-small cell lung cancer (NSCLC)
Phase 2 data released November 26, 2018. ORR trilaciclib 56.0%, placebo 63.5%.
Trilaciclib plus Tecentriq
First-line small-cell lung cancer
Phase 1b preliminary released at ASCO 2018 - 17% PR. Additional data due 1Q 2019.
G1T38 plus Faslodex
ER+ breast cancer
Phase 2a top-line data released March 5, 2018 - consequences of chemotherapy-induced myelosuppression versus placebo. PFS/ORR rates not currently significant but data are immature.
First-line small-cell lung cancer
Phase 2 preliminary data December 19, 2018 noted ORR 13% vs placebo 23%.
Second/third-line small-cell lung cancer
Phase 1/2 preliminary data due 2019.
ER+, HER2- breast cancer

Latest News

  1. G1 Therapeutics to Report Fourth Quarter and Full-Year 2018 Financial Results on February 28, 2019
  2. Glancy Prongay & Murray LLP Continues Investigation on Behalf of G1 Therapeutics, Inc. Investors (GTHX)
  3. Are Insiders Selling G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock?
  4. 5 Domestic Stocks to Gain From Thaw in Trade Talks
  5. G1 THERAPEUTICS Enters Oversold Territory
  6. From Iqvia to Red Hat: These execs raked in millions from stock sales in 2018
  7. G1 Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference
  8. Why G1 Therapeutics Got Hammered 42.6% Today
  9. G1 Therapeutics Investors Recoil, Analysts Bullish In Wake Of Trilaciclib Results
  10. G1 Therapeutics stock dives on cancer-related infection drug study results
  11. G1 Therapeutics Announces Positive Topline Results from Randomized Phase 2 Trial of Trilaciclib Showing Multi-Lineage Myelopreservation Benefits in 2nd-/3rd-Line Small Cell Lung Cancer
  12. G1 Therapeutics, Inc. (GTHX): Are Hedge Funds Right About This Stock?
  13. New Research Coverage Highlights G1 THERAPEUTICS, Schlumberger, Adient, Camping World, Nutanix, and CNH Industrial N.V — Consolidated Revenues, Company Growth, and Expectations for 2018
  14. Preliminary Results from Randomized Phase 2 Trial Demonstrate Trilaciclib Improved Progression-Free Survival in Combination with Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer
  15. The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial
  16. G1 Therapeutics Announces Positive Myelopreservation Data from Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Trilaciclib in Combination with Chemotherapy/Tecentriq® in First-Line Small Cell Lung Cancer
  17. Edited Transcript of GTHX.O earnings conference call or presentation 7-Nov-18 9:30pm GMT
  18. G1 Therapeutics Reports Third Quarter 2018 Financial Results and Corporate Update